Bright Minds Biosciences Files 6-K with Financials
Ticker: DRUG · Form: 6-K · Filed: Aug 15, 2024 · CIK: 1827401
Sentiment: neutral
Topics: financials, reporting
Related Tickers: BMBS
TL;DR
BMBS dropped Q1-Q3 2024 financials, check em out.
AI Summary
Bright Minds Biosciences Inc. filed a Form 6-K on August 15, 2024, reporting its condensed interim consolidated financial statements for the nine months ended June 30, 2024, and 2023. The filing also includes management's discussion and analysis. The company is incorporated in Delaware and has its principal executive office in New York, NY.
Why It Matters
This filing provides investors with updated financial performance and management's perspective on the company's operations for the first nine months of the fiscal year.
Risk Assessment
Risk Level: medium — Form 6-K filings often contain unaudited financial information and updates that can lead to stock price volatility.
Key Players & Entities
- BRIGHT MINDS BIOSCIENCES INC. (company) — Filer
- 0001062993-24-015119 (filing_id) — Accession Number
- 20240815 (date) — Filing Date
- 20240630 (date) — Reporting Period End Date
- 19 VESTRY STREET, NEW YORK, NY 10013 (address) — Principal Executive Office
FAQ
What period do the submitted financial statements cover?
The submitted financial statements cover the nine months ended June 30, 2024, and 2023.
What is the company's principal executive office address?
The company's principal executive office is located at 19 Vestry Street, New York, NY 10013.
What is the SEC file number for Bright Minds Biosciences Inc.?
The SEC file number for Bright Minds Biosciences Inc. is 001-40997.
What type of report is being filed?
A Form 6-K report is being filed.
What exhibits are submitted with this Form 6-K?
Exhibits submitted include Condensed Interim Consolidated Financial Statements for the nine months ended June 30, 2024 and 2023, and Management's Discussion and Analysis.
Filing Stats: 241 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2024-08-14 21:15:31
Filing Documents
- form6k.htm (6-K) — 6KB
- exhibit99-1.htm (EX-99.1) — 336KB
- exhibit99-2.htm (EX-99.2) — 181KB
- exhibit99-3.htm (EX-99.3) — 7KB
- exhibit99-4.htm (EX-99.4) — 7KB
- exhibit99-2x002.jpg (GRAPHIC) — 24KB
- exhibit99-2x003.jpg (GRAPHIC) — 55KB
- exhibit99-2x004.jpg (GRAPHIC) — 35KB
- 0001062993-24-015119.txt ( ) — 695KB
Management's Discussion and Analysis for the Third Quarter Ended June 30, 2024
Management's Discussion and Analysis for the Third Quarter Ended June 30, 2024 99.3 Certification of Interim Filings - CEO 99.4 Certification of Interim Filings - CFO SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BRIGHT MINDS BIOSCIENCES INC. /s/ Ryan Cheung __________________________ Ryan Cheung Chief Financial Officer Date: August 14, 2024